Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

NCT02433158 is registered in ClinicalTrials.gov with GlycoMimetics Incorporated as lead sponsor.

NCT NCT02433158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02433158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Evaluate the Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
Lead sponsor
GlycoMimetics Incorporated
Phase
Phase 3
Overall status
Terminated
Start date
December 16, 2015
Completion date
November 15, 2019
Enrollment
154 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

pain crisis, sickle cell anemia, sickle cell disease, sickle cell disorders, vaso-occlusive crisis